Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2016-01-04 Capital/Financing Update
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Share buybacks / Liquidity contracts Information related to liquidity contracts
Capital/Financing Update Classification · 99% confidence The document is a press release dated January 4, 2016, providing an update on the company's liquidity agreement, specifically detailing the number of shares and cash held in the liquidity account as of December 31, 2015, compared to June 30, 2015. This content relates to the company's capital structure and financing arrangements, specifically concerning the shares held by the market maker/liquidity provider. This fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It is a specific update on financing/capital management.
2016-01-04 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan annuel du contrat de liquidité Pixium Vision contracté avec la Société de Bourse Gilbert Dupont" (Annual balance of the liquidity contract...). It reports the status of a liquidity contract (share count and cash balance) as of December 31, 2015, and compares it to the previous semi-annual balance (June 30, 2015). This type of announcement, detailing the status of market-making or liquidity agreements, is a specific regulatory disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It is a specific financial/regulatory update related to market operations. Given the options, this specific disclosure about the liquidity contract balance fits best under general Regulatory Filings (RNS) or potentially a specialized financing/capital update, but RNS is the most appropriate general category for specific, non-core financial disclosures that don't match other specific codes like DIV, NAV, or CAP. Since it is a formal, periodic report on a specific agreement, RNS is the best fit as a regulatory disclosure.
2016-01-04 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is titled with a headline announcing that Pixium Vision has filed for a CE Mark for its IRIS® II system. The text explicitly mentions a 'regulatory filing for CE mark' and discusses the submission of comprehensive information (design, preclinical data, clinical evaluation) to a notified body. This type of announcement, detailing a significant regulatory submission or approval process for a product, is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update, but since it is a press release announcing a specific regulatory action (CE Mark filing), RNS is the most appropriate general regulatory category, as it is not a standard financial report (10-K, IR, ER) or a management/board change (MANG, DIRS). Given the context of a press release announcing a regulatory step, RNS serves as the best fit among the provided options, as it is a general regulatory announcement.
2015-12-21 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated December 14, 2015, announcing that Pixium Vision has received authorization from the French regulatory authority (ANSM) to start a clinical trial for its IRIS® II vision restoration system. This type of announcement, detailing regulatory milestones, clinical trial progress, and strategic updates, is characteristic of general corporate news releases. It is not a formal periodic report (10-K, IR), a specific financial filing (ER, MRQ), or a document focused solely on management changes (MANG) or dividends (DIV). Since it is a general announcement of a significant corporate event (regulatory approval for a clinical trial), and it doesn't fit the specific categories like Capital/Financing (CAP) or Legal Proceedings (LTR), the most appropriate general category for significant, non-standard regulatory/corporate news is Regulatory Filings (RNS), which serves as a broad category for important announcements that don't fit elsewhere, or potentially a general Investor Relations document. Given the context of a press release detailing a regulatory clearance for a medical device trial, RNS is the best fit as a catch-all for significant, non-periodic corporate news releases.
2015-12-14 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated December 14, 2015, announcing that Pixium Vision received approval from the French regulatory authority (ANSM) to implant its IRIS® II system in a clinical study. It details the technology, the CEO's comments, and future commercialization plans. This type of announcement, which communicates a significant operational or regulatory milestone via a press release format, does not fit the specific definitions for 10-K, IR, ER, or DEF 14A. It is not a transcript (CT), a formal audit report (AR), or a management discussion (MDA). Since it is a general, time-sensitive announcement of a regulatory event that doesn't fit the other specific categories (like M&A, Dividend, or Director Dealing), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory update, although it is essentially a press release announcing regulatory progress.
2015-12-14 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated December 11, 2015, announcing that Pixium Vision received the 2016 *Observeur du design* Award for its IRIS® system. It contains company updates, product information, clinical trial status, and contact details, concluding with a standard disclaimer. This format is characteristic of an initial announcement of news or an event, rather than a comprehensive financial report (like 10-K or IR) or a transcript. Since it is a general news announcement that doesn't fit the specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), the most appropriate general category for non-financial, non-regulatory-specific corporate news announcements is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate communications that are often released via regulatory channels.
2015-12-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.